Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial

Kamilu M Karaye, Hadiza Sa'idu, Suleiman A Balarabe, Naser A Ishaq, Bushra Sanni, Haruna Abubakar, Baba Lawan Mohammed, Tijjani Abdulsalam, Jamilu Tukur, Idris Y Mohammed, Kamilu M Karaye, Hadiza Sa'idu, Suleiman A Balarabe, Naser A Ishaq, Bushra Sanni, Haruna Abubakar, Baba Lawan Mohammed, Tijjani Abdulsalam, Jamilu Tukur, Idris Y Mohammed

Abstract

Background: We studied the efficacy and safety of selenium supplementation in patients who had peripartum cardiomyopathy (PPCM) and selenium deficiency.

Methods: We randomly assigned 100 PPCM patients with left ventricular ejection fraction (LVEF) < 45% and selenium deficiency (< 70 μg/L) to receive either oral Selenium (L-selenomethionine) 200 μg/day for 3 months or nothing, in addition to recommended therapy, in an open-label randomised trial. The primary outcome was a composite of persistence of heart failure (HF) symptoms, unrecovered LV systolic function (LVEF < 55%) or death from any cause.

Results: Over a median of 19 months, the primary outcome occurred in 36 of 46 patients (78.3%) in the selenium group and in 43 of 54 patients (79.6%) in the control group (hazard ratio [HR] 0.69; 95% confidence interval [CI] 0.43-1.09; p = 0.113). Persistence of HF symptoms occurred in 18 patients (39.1%) in the selenium group and in 37 patients (68.5%) in the control group (HR 0.53; 95% CI 0.30-0.93; p = 0.006). LVEF < 55% occurred in 33 patients (71.7%) in the selenium group and in 38 patients (70.4%) in the control group (HR 0.91; 95% CI 0.57-1.45; p = 0.944). Death from any cause occurred in 3 patients (6.5%) in the selenium group and in 9 patients (16.7%) in the control group (HR 0.37; 95% CI 0.10-1.37; p = 0.137).

Conclusions: In this study, selenium supplementation did not reduce the risk of the primary outcome, but it significantly reduced HF symptoms, and there was a trend towards a reduction of all-cause mortality.

Clinical trial registration: ClinicalTrials.gov Identifier: NCT03081949.

Keywords: Mortality; Nigeria; Outcomes; PEACE registry; Peripartum cardiomyopathy; Selenium supplementation.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Enrolment and follow-up of patients. LVEF left ventricular ejection fraction, GPX glutathione peroxidise. All the patients who underwent randomisation were included in the primary analysis
Fig. 2
Fig. 2
Composite outcome events. Composite outcome: the primary outcome was a composite of persistence of HF symptoms, unrecovered LVEF or death from any cause. The cumulative incidence of the primary outcome was estimated with the use of the Kaplan–Meier method; hazard ratios and 95% confidence interval was estimated with the use of Cox regression models, stratified according to selenium supplementation

References

    1. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12(8):767–778. doi: 10.1093/eurjhf/hfq120.
    1. Karaye KM, Lindmark K, Henein MY. One-year survival in Nigerians with peripartum cardiomyopathy. Heart Views. 2016;17:55–61. doi: 10.4103/1995-705X.185114.
    1. Karaye KM, Lindmark K, Henein MY. Right ventricular systolic dysfunction and remodelling in Nigerians with peripartum cardiomyopathy: a longitudinal study. BMC Cardiovasc Disord. 2016;16:27. doi: 10.1186/s12872-016-0204-8.
    1. Karaye KM, Ishaq NA, Sa'idu H, Balarabe SA, Talle MA, Isa MS, et al. Incidence, clinical characteristics, and risk factors of peripartum cardiomyopathy in Nigeria: results from the peripartum cardiomyopathy in Nigeria Registry. ESC Heart Fail. 2020;7(1):235–243.
    1. Cenac A, Simonoff M, Moretto P, Djibo A. A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa. Int J Cardiol. 1992;36:57–59. doi: 10.1016/0167-5273(92)90108-F.
    1. Karaye KM, Yahaya IA, Lindmark K, Henein MY. Serum selenium and ceruloplasmin in Nigerians with peripartum cardiomyopathy. Int J Mol Sci. 2015;16:7644–7654. doi: 10.3390/ijms16047644.
    1. Yang GQ, Ge KY, Chen JS, Chen XS. Selenium-related en-demic diseases and the daily selenium requirement of humans. World Rev Nutr Diet. 1988;55:98–152. doi: 10.1159/000415560.
    1. Observations on effect of sodium selenite in prevention of Keshan disease. Chin Med J. 1979;92:471–6.
    1. Sunde RA. Selenium. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, editors. Modern nutrition in health and disease. 11. Philadelphia: Lippincott Williams & Wilkins; 2012. pp. 225–2237.
    1. Karaye KM, Mohammed IY, Ogah OS, Basil N, Okeahialam BN. Rationale and design for the peripartum cardiomyopathy in Nigeria (PEACE) registry. Int Cardiovasc Forum J. 2017;12:12–17.
    1. World Medical Association World Medical Association declaration of Helsinki, ethical principles for medical research involving human subjects. J Postgrad Med. 2002;48:206–208.
    1. Sliwa K, Forster O, Tibazarwa K, Libhaber E, Becker A, Yip A, et al. Long-term outcome of peripartum cardiomyopathy in a population with high seropositivity for human immunodeficiency virus. Int J Cardiol. 2011;147(2):202–208. doi: 10.1016/j.ijcard.2009.08.022.
    1. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (investigations of pregnancy—associated cardiomyopathy) J Am Coll Cardiol. 2015;66(8):905–914. doi: 10.1016/j.jacc.2015.06.1309.
    1. Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, et al. Long-term follow-up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co-morbidities. Eur J Heart Fail. 2019 doi: 10.1002/ejhf.1624.
    1. Marklund SL, Holme E, Hellner L. Superoxide dismutase in extracellular fluids. Clin Chim Acta. 1982;126:41–51. doi: 10.1016/0009-8981(82)90360-6.
    1. Ermakov V, Jovanović L. Selenium deficiency as a consequence of human activity and its correction. J Geochem Explor. 2010;107:193–199. doi: 10.1016/j.gexplo.2010.07.004.
    1. Selenium. Fact sheet for health professionals. Office of Dietary Supplements, National Institutes of Health. . Accessed 8 Feb 2020.
    1. Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, et al. Effects of selenium supplementation on cardiovascular disease incidence and mortality: secondary analyses in a randomised clinical trial. Am J Epidemiol. 2006;163:694–699. doi: 10.1093/aje/kwj097.
    1. Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21(7):827–843. doi: 10.1002/ejhf.1493.
    1. Karaye KM, Saidu H, Ishaq NA, Balarabe SA, Mohammed IY. Selenium supplementation in patients with peripartum cardiomy. J Am Coll Cardiol. 2020;75(11):662. doi: 10.1016/S0735-1097(20)31289-4.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj